OBJECTIVE: Mesenchymal stem cells (MSC) have multiorgan differentiation capacity, providing the potential for prenatal treatment of genetic disorders. We address the question if in utero transplantation of MSC results in short-term organ-specific engraftment in the fetal sheep. STUDY DESIGN: Sheep fetal liver-derived MSC selected by adherence culture (passage 1) were transplantated into the fetal peritoneal cavity with ultrasound-guidance (mean gestational age, 59 days). After 14 days recipient fetuses were analyzed by fluorescence-activated cell sorting (FACS), real-time polymerase chain reaction (PCR), and immunohistochemistry. RESULTS: Fetuses (n = 11) were transplanted with 7.7 x 10(6) MSCs (mean). All surviving fetuses (n = 5) showed engraftment with mean levels of 3.2% (lung), 0.8% (spleen), 0.6% (liver, brain), 0.4% (bone marrow), 0.1% (blood, thymus), and <0.1% (kidneys) by flow cytometry. Immunohistochemistry showed organ-specific distribution. CONCLUSION: In utero transplantation of allogeneic MSC results in low level, multiorgan engraftment at 14 days post transplant. This supports the potential of in utero MSC transplantation for the treatment of nonhematopoietic genetic disorders of the fetus.
OBJECTIVE: Mesenchymal stem cells (MSC) have multiorgan differentiation capacity, providing the potential for prenatal treatment of genetic disorders. We address the question if in utero transplantation of MSC results in short-term organ-specific engraftment in the fetal sheep. STUDY DESIGN:Sheep fetal liver-derived MSC selected by adherence culture (passage 1) were transplantated into the fetal peritoneal cavity with ultrasound-guidance (mean gestational age, 59 days). After 14 days recipient fetuses were analyzed by fluorescence-activated cell sorting (FACS), real-time polymerase chain reaction (PCR), and immunohistochemistry. RESULTS: Fetuses (n = 11) were transplanted with 7.7 x 10(6) MSCs (mean). All surviving fetuses (n = 5) showed engraftment with mean levels of 3.2% (lung), 0.8% (spleen), 0.6% (liver, brain), 0.4% (bone marrow), 0.1% (blood, thymus), and <0.1% (kidneys) by flow cytometry. Immunohistochemistry showed organ-specific distribution. CONCLUSION: In utero transplantation of allogeneic MSC results in low level, multiorgan engraftment at 14 days post transplant. This supports the potential of in utero MSC transplantation for the treatment of nonhematopoietic genetic disorders of the fetus.
Authors: Brett Hall; Jennifer Dembinski; A Kate Sasser; Matus Studeny; Michael Andreeff; Frank Marini Journal: Int J Hematol Date: 2007-07 Impact factor: 2.490
Authors: Rafael Moreno; Itziar Martínez-González; Marta Rosal; Marga Nadal; Jordi Petriz; Eduard Gratacós; Josep M Aran Journal: Stem Cells Dev Date: 2011-06-01 Impact factor: 3.272
Authors: Christopher D Porada; Duygu D Harrison-Findik; Chad Sanada; Vincent Valiente; David Thain; Paul J Simmons; Graça Almeida-Porada; Esmail D Zanjani Journal: Exp Hematol Date: 2008-12 Impact factor: 3.084
Authors: Maximilian Y Emmert; Benedikt Weber; Petra Wolint; Thomas Frauenfelder; Steffen M Zeisberger; Luc Behr; Sebastien Sammut; Jacques Scherman; Chad E Brokopp; Ruth Schwartländer; Viola Vogel; Peter Vogt; Jürg Grünenfelder; Hatem Alkadhi; Volkmar Falk; Andreas Boss; Simon P Hoerstrup Journal: PLoS One Date: 2013-03-22 Impact factor: 3.240